Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Ibuprofen administration attenuates serum TNF-alpha levels, hepatic glutathione depletion, hepatic apoptosis and mouse mortality after Fas stimulation.

Cazanave S, Vadrot N, Tinel M, Berson A, Lettéron P, Larosche I, Descatoire V, Feldmann G, Robin MA, Pessayre D.

Toxicol Appl Pharmacol. 2008 Sep 15;231(3):336-43. doi: 10.1016/j.taap.2008.05.010. Epub 2008 May 20.

PMID:
18572215
2.

The anti-inflammatory drug, nimesulide (4-nitro-2-phenoxymethane-sulfoanilide), uncouples mitochondria and induces mitochondrial permeability transition in human hepatoma cells: protection by albumin.

Berson A, Cazanave S, Descatoire V, Tinel M, Grodet A, Wolf C, Feldmann G, Pessayre D.

J Pharmacol Exp Ther. 2006 Jul;318(1):444-54. Epub 2006 Apr 14.

PMID:
16617166
3.

Subliminal Fas stimulation increases the hepatotoxicity of acetaminophen and bromobenzene in mice.

Tinel M, Berson A, Vadrot N, Descatoire V, Grodet A, Feldmann G, Thénot JP, Pessayre D.

Hepatology. 2004 Mar;39(3):655-66.

PMID:
14999684
4.

Downregulation of cytochromes P450 in growth-stimulated rat hepatocytes: role of c-Myc induction and impaired C/EBP binding to DNA.

Tinel M, Berson A, Elkahwaji J, Cresteil T, Beaune P, Pessayre D.

J Hepatol. 2003 Aug;39(2):171-8.

PMID:
12873812
5.

Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice.

Demeilliers C, Maisonneuve C, Grodet A, Mansouri A, Nguyen R, Tinel M, Lettéron P, Degott C, Feldmann G, Pessayre D, Fromenty B.

Gastroenterology. 2002 Oct;123(4):1278-90.

PMID:
12360488
6.

Prolonged, but not acute, glutathione depletion promotes Fas-mediated mitochondrial permeability transition and apoptosis in mice.

Haouzi D, Lekehal M, Tinel M, Vadrot N, Caussanel L, Lettéron P, Moreau A, Feldmann G, Fau D, Pessayre D.

Hepatology. 2001 May;33(5):1181-8.

PMID:
11343247
7.

Interleukin-2 overexpresses c-myc and down-regulates cytochrome P-450 in rat hepatocytes.

Tinel M, Elkahwaji J, Robin MA, Fardel N, Descatoire V, Haouzi D, Berson A, Pessayre D.

J Pharmacol Exp Ther. 1999 May;289(2):649-55.

PMID:
10215635
8.

Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy.

Elkahwaji J, Robin MA, Berson A, Tinel M, Lettéron P, Labbe G, Beaune P, Elias D, Rougier P, Escudier B, Duvillard P, Pessayre D.

Biochem Pharmacol. 1999 Apr 15;57(8):951-4.

PMID:
10086330
9.

A role for transforming growth factor alpha as an inducer of astrogliosis.

Rabchevsky AG, Weinitz JM, Coulpier M, Fages C, Tinel M, Junier MP.

J Neurosci. 1998 Dec 15;18(24):10541-52.

10.

Regulation of growth factor gene expression in degenerating motoneurons of the murine mutant wobbler: a cellular patch-sampling/RT-PCR study.

Junier MP, Legendre P, Esguerra CV, Tinel M, Coulpier M, Dreyfus PA, Bähr M.

Mol Cell Neurosci. 1998 Oct;12(3):168-77.

PMID:
9790737
11.

The interleukin-2 receptor down-regulates the expression of cytochrome P450 in cultured rat hepatocytes.

Tinel M, Robin MA, Doostzadeh J, Maratrat M, Ballet F, Fardel N, el Kahwaji J, Beaune P, Daujat M, Labbe G, et al.

Gastroenterology. 1995 Nov;109(5):1589-99.

PMID:
7557143
12.

Cytochrome P4502B follows a vesicular route to the plasma membrane in cultured rat hepatocytes.

Robin MA, Maratrat M, Loeper J, Durand-Schneider AM, Tinel M, Ballet F, Beaune P, Feldmann G, Pessayre D.

Gastroenterology. 1995 Apr;108(4):1110-23.

PMID:
7698579
13.
14.

What changes drug metabolism in critically ill patients? Two preliminary studies in isolated human hepatocytes.

Park GR, Pichard L, Tinel M, Larroque C, Elston A, Domerque J, Dexionne B, Maurel P.

Anaesthesia. 1994 Mar;49(3):188-9.

15.

Administration of high doses of human recombinant interleukin-2 decreases the expression of several cytochromes P-450 in the rat.

Thal C, el Kahwaji J, Loeper J, Tinel M, Doostzadeh J, Labbe G, Leclaire J, Beaune P, Pessayre D.

J Pharmacol Exp Ther. 1994 Jan;268(1):515-21.

PMID:
8301593
16.

Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes.

Horsmans Y, Lannes D, Larrey D, Tinel M, Letteron P, Loeper J, Pessayre D.

Xenobiotica. 1991 Dec;21(12):1559-70.

PMID:
1785203
17.

Pharmacogenetics of human erythrocyte thiopurine methyltransferase activity in a French population.

Tinel M, Berson A, Pessayre D, Letteron P, Cattoni MP, Horsmans Y, Larrey D.

Br J Clin Pharmacol. 1991 Dec;32(6):729-34.

18.

Inhibition of rat liver estrogen 2/4-hydroxylase activity by troleandomycin: comparison with erythromycin and roxithromycin.

Fisher D, Labbe G, Berson A, Tinel M, Loeper J, Larrey D, Pessayre D.

J Pharmacol Exp Ther. 1990 Sep;254(3):1120-7.

PMID:
2395109
19.

Metabolic activation of the new tricyclic antidepressant tianeptine by human liver cytochrome P450.

Larrey D, Tinel M, Lettéron P, Maurel P, Loeper J, Belghiti J, Pessayre D.

Biochem Pharmacol. 1990 Aug 1;40(3):545-50.

PMID:
2383287
20.

Differences in hepatic drug accumulation and enzyme induction after chronic amiodarone feeding of two rat strains: role of the hydroxylator phenotype?

Pirovino M, Honegger U, Müller O, Zysset T, Küpfer A, Tinel M, Pessayre D.

Br J Pharmacol. 1990 Jan;99(1):35-40.

21.

Metabolic activation of the antidepressant tianeptine. II. In vivo covalent binding and toxicological studies at sublethal doses.

Letteron P, Labbe G, Descatoire V, Degott C, Loeper J, Tinel M, Larrey D, Pessayre D.

Biochem Pharmacol. 1989 Oct 1;38(19):3247-51.

PMID:
2818624
22.

Metabolic activation of the antidepressant tianeptine. I. Cytochrome P-450-mediated in vitro covalent binding.

Letteron P, Descatoire V, Tinel M, Maurel P, Labbe G, Loeper J, Larrey D, Freneaux E, Pessayre D.

Biochem Pharmacol. 1989 Oct 1;38(19):3241-6.

PMID:
2818623
23.

Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients.

Larrey D, Babany G, Tinel M, Freneaux E, Amouyal G, Habersetzer F, Letteron P, Pessayre D.

Br J Clin Pharmacol. 1989 Sep;28(3):297-304.

24.

Genetic predisposition to drug hepatotoxicity: role in hepatitis caused by amineptine, a tricyclic antidepressant.

Larrey D, Berson A, Habersetzer F, Tinel M, Castot A, Babany G, Lettéron P, Freneaux E, Loeper J, Dansette P, et al.

Hepatology. 1989 Aug;10(2):168-73.

PMID:
2744728
25.

Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides.

Tinel M, Descatoire V, Larrey D, Loeper J, Labbe G, Letteron P, Pessayre D.

J Pharmacol Exp Ther. 1989 Aug;250(2):746-51.

PMID:
2527301
26.

Inhibitory effects of nilutamide, a new androgen receptor antagonist, on mouse and human liver cytochrome P-450.

Babany G, Tinel M, Letteron P, Freneaux E, Berson A, Larrey D, Pessayre D.

Biochem Pharmacol. 1989 Mar 15;38(6):941-7.

PMID:
2930595
27.

Extensive oxidative metabolism of dextromethorphan in patients with almitrine neuropathy.

Belec L, Larrey D, De Cremoux H, Tinel M, Louarn F, Pessayre D, Gherardi R.

Br J Clin Pharmacol. 1989 Mar;27(3):387-90.

28.

Genetically determined oxidation polymorphism and drug hepatotoxicity. Study of 51 patients.

Larrey D, Tinel M, Amouyal G, Freneaux E, Berson A, Fouin-Fortunet H, Babany G, Letteron P, Iglicki F, Slama JL, et al.

J Hepatol. 1989 Mar;8(2):158-64.

PMID:
2715619
29.

Polymorphism of dextromethorphan oxidation in a French population.

Larrey D, Amouyal G, Tinel M, Letteron P, Berson A, Labbe G, Pessayre D.

Br J Clin Pharmacol. 1987 Nov;24(5):676-9.

30.

Methoxsalen decreases the metabolic activation and prevents the hepatotoxicity and nephrotoxicity of chloroform in mice.

Lettéron P, Degott C, Labbe G, Larrey D, Descatoire V, Tinel M, Pessayre D.

Toxicol Appl Pharmacol. 1987 Nov;91(2):266-73.

PMID:
3118512
31.

Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives.

Tinel M, Belghiti J, Descatoire V, Amouyal G, Letteron P, Geneve J, Larrey D, Pessayre D.

Biochem Pharmacol. 1987 Mar 15;36(6):951-5.

PMID:
3494453
32.

The drug methoxsalen, a suicide substrate for cytochrome P-450, decreases the metabolic activation, and prevents the hepatotoxicity, of carbon tetrachloride in mice.

Labbe G, Descatoire V, Letteron P, Degott C, Tinel M, Larrey D, Carrion-Pavlov Y, Geneve J, Amouyal G, Pessayre D.

Biochem Pharmacol. 1987 Mar 15;36(6):907-14.

PMID:
3105541
33.

Metabolic activation of the tricyclic antidepressant amineptine--II. Protective role of glutathione against in vitro and in vivo covalent binding.

Geneve J, Degott C, Letteron P, Tinel M, Descatoire V, Larrey D, Amouyal G, Pessayre D.

Biochem Pharmacol. 1987 Feb 1;36(3):331-7.

PMID:
3814175
34.

Metabolic activation of the tricyclic antidepressant amineptine--I. Cytochrome P-450-mediated in vitro covalent binding.

Geneve J, Larrey D, Letteron P, Descatoire V, Tinel M, Amouyal G, Pessayre D.

Biochem Pharmacol. 1987 Feb 1;36(3):323-9.

PMID:
3814174
35.

Pre- or post-treatment with methoxsalen prevents the hepatotoxicity of acetaminophen in mice.

Letteron P, Descatoire V, Larrey D, DeGott C, Tinel M, Geneve J, Pessayre D.

J Pharmacol Exp Ther. 1986 Nov;239(2):559-67.

PMID:
3772810
36.

Inactivation and induction of cytochrome P-450 by various psoralen derivatives in rats.

Letteron P, Descatoire V, Larrey D, Tinel M, Geneve J, Pessayre D.

J Pharmacol Exp Ther. 1986 Aug;238(2):685-92.

PMID:
3735138
37.

Formation of an inactive cytochrome P-450Fe(II)-metabolite complex after administration of amiodarone in rats, mice and hamsters.

Larrey D, Tinel M, Letteron P, Geneve J, Descatoire V, Pessayre D.

Biochem Pharmacol. 1986 Jul 1;35(13):2213-20.

PMID:
3729976
38.

Effects of pregnancy on the toxicity and metabolism of acetaminophen in mice.

Larrey D, Letteron P, Foliot A, Descatoire V, Degott C, Geneve J, Tinel M, Pessayre D.

J Pharmacol Exp Ther. 1986 Apr;237(1):283-91.

PMID:
3083096
39.

Inactivation of cytochrome P-450 by the drug methoxsalen.

Fouin-Fortunet H, Tinel M, Descatoire V, Letteron P, Larrey D, Geneve J, Pessayre D.

J Pharmacol Exp Ther. 1986 Jan;236(1):237-47.

PMID:
3941395
40.

Mechanism for isaxonine hepatitis. II. Protective role of glutathione and toxicological studies in mice.

Fouin-Fortunet H, Lettéron P, Tinel M, Degott C, Flejou JF, Pessayre D.

J Pharmacol Exp Ther. 1984 Jun;229(3):851-8.

PMID:
6547180
41.

Mechanism for isaxonine hepatitis. I. Metabolic activation by mouse and human cytochrome P-450.

Lettéron P, Fouin-Fortunet H, Tinel M, Danan G, Belghiti J, Pessayre D.

J Pharmacol Exp Ther. 1984 Jun;229(3):845-50.

PMID:
6547179
42.

Protective effect of 16,16-dimethyl prostaglandin E2 on the hepatotoxicity of bromobenzene in mice.

Funck-Brentano C, Tinel M, Degott C, Letteron P, Babany G, Pessayre D.

Biochem Pharmacol. 1984 Jan 1;33(1):89-96.

PMID:
6704144
44.

Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione.

Pessayre D, Tinel M, Larrey D, Cobert B, Funck-Brentano C, Babany G.

J Pharmacol Exp Ther. 1983 Mar;224(3):685-91.

PMID:
6600790
45.

Self-induction by oleandomycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. Comparison with troleandomycin.

Pessayre D, Descatoire V, Tinel M, Larrey D.

J Pharmacol Exp Ther. 1982 Apr;221(1):215-21. No abstract available.

PMID:
6977641

Supplemental Content

Support Center